Earnings calls

Strides Pharma concall ledger

Every earnings call for STAR — management tone, guidance, KPIs and promise tracking, quarter by quarter.

STAR · 5 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 18 May 2026Call held 18 May 2026

STAR Q4 FY26 Earnings Call Transcript & Analysis

Revenue48,587 million+6% YoYEBITDA₹925 cr+15% YoYEBITDA Margin19%Reported PAT₹575 cr+40% YoYReported EPS₹60.3

Revenue 48587 million (+6% YoY); EBITDA ₹925 cr (+15% YoY); EBITDA Margin 19%. FY26 Revenue of INR48,587 million, up 6.4% YoY.

Q3 FY26Published 30 Jan 2026Call held 30 Jan 2026

Revenue₹1,191.92 cr+4% YoYEBITDA₹236 cr+12% YoYEBITDA Margin19.8%Reported PAT₹208 crGross Margin59.8%

Revenue ₹1,192 cr (+4% YoY); EBITDA ₹236 cr (+12% YoY); EBITDA Margin 19.8%. Gross margins exceeded 60%, with overall gross margins at 59.8%.

Q2 FY26Published 31 Oct 2025Call held 31 Oct 2025

EBITDA₹232 cr+25% YoYEBITDA Margin19%Reported PAT₹132 crNet Debt₹1,449 crROCE16%

EBITDA (Q2) ₹232 cr (+25% YoY); EBITDA Margin (Q2) 19%; Reported PAT (Q2) ₹132 cr. Revenue grew by 4.6% YoY in Q2 FY26.

Q1 FY26Published 29 Jul 2025Call held 29 Jul 2025

Revenue₹1,120 crEBITDA₹218 cr+15% YoYEBITDA Margin19.5%Reported PAT₹106 cr

Revenue ₹1,120 cr; EBITDA ₹218 cr (+15% YoY); EBITDA Margin 19.5%. Revenue of ₹1,120 crores in Q1 FY26.

Q4 FY25Published 27 May 2025Call held 27 May 2025

FY25 EBITDA₹802.8 cr+37% YoYFY25 EBITDA Margin17.6%FY25 Reported EPS₹44.05FY25 ROCE14.9%

FY25 EBITDA ₹803 cr (+37% YoY); FY25 EBITDA Margin 17.6%; FY25 Reported EPS ₹44.05. FY25 Revenue grew 17.2%, exceeding guidance of 12-15%.